However, in our AD mouse model, Aβ pathology develops as a chronic, progressive accumulation of Aβ deposits and our mice were tested for BDNF elevation at six to seven months after treatment with fingolimod for one to two months. This evidence concerns the gene BDNF and Alzheimer disease.